Amylyx Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent
Amylyx Pharmaceuticals, Inc. (AMLX) reported Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent of -0.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate · last filed 2025-03-04
- Amylyx Pharmaceuticals, Inc. effective income tax rate reconciliation, change in enacted tax rate, percent for fiscal 2024 was -0.50%, a 123.81% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. effective income tax rate reconciliation, change in enacted tax rate, percent for fiscal 2023 was 2.10%.
- Amylyx Pharmaceuticals, Inc. effective income tax rate reconciliation, change in enacted tax rate, percent for fiscal 2022 was -0.20%.
- Amylyx Pharmaceuticals, Inc. effective income tax rate reconciliation, change in enacted tax rate, percent for fiscal 2021 was -0.20%.
| Period end | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent 12 month |
|---|---|
| 2024-12-31 | -0.50% 10-K · filed 2025-03-04 |
| 2023-12-31 | 2.10% 10-K · filed 2025-03-04 |
| 2022-12-31 | -0.20% 10-K · filed 2024-02-22 |
| 2021-12-31 | -0.20% 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |